New DNA sequencer could make genetic testing cheaper and faster
NCT ID NCT07160010
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares a new DNA sequencing platform (MGI) against the current standard (Illumina) for diagnosing hereditary cancers like breast and ovarian cancer, Lynch syndrome, and intestinal polyposis. Researchers will analyze 248 patient samples using both platforms to see if the new one is just as accurate. If it works, it could offer a more affordable option for genetic testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could validate a more affordable sequencing platform for diagnosing hereditary cancers and genetic disorders, potentially expanding access to genetic testing.
- What could go wrong
- This is an early-stage validation study, not a treatment trial. The new platform may not match the accuracy of the current gold standard, and results may not apply to other tests or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a new drug combo revive Immunotherapy's power against resistant tumors?